Pars Plana Vitrectomy
14
1
1
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
14.3%
2 terminated out of 14 trials
71.4%
-15.2% vs benchmark
7%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (14)
Influence of HFNO on Spontaneous Breathing Support in Patients of Different ASA Risk During Moderate Multimodal Analgo-sedation for Pars Plana Vitrectomy
Necessity of Post-operative Eye Drops
Safety and Efficacy of HydroLenz for Vitrectomy-Induced Lens Opacities
Effectiveness and Safety of 25-Gauge Needle-Assisted Phacoemulsification of Dislocated Intravitreal Lens Nucleus
INTRAOCULAR PRESSURE MEASUREMENT AT the END of PARS PLANA VITRECTOMY
Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema
Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial
Establishment and Validation of a Risk Prediction Model for Long-term Low Vision After Vitrectomy in PDR Patients
A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy
Quantification of Silicone Oil Emulsification After Pars Plana Vitrectomy
Suprachoroidal Hemorrhage Associated With Pars Plana Vitrectomy
Vitrectomy With Internal Limiting Membrane Peeling for Myopic Traction Maculopathy
Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment
SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy